Is the use of COX-2 inhibitors in gastroenterology cost-effective?
Graham
David Y
DY
Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX 77030 USA. dgraham@bcm.tmc.edu
Chan
Francis K L
FK
D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000191:economics* / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D010437:Peptic Ulcer / Q000139:chemically induced*
D016861:Cyclooxygenase Inhibitors